Epidemiologic studies have shown that a low level of high-density lipoprotein (HDL) cholesterol is a risk factor for cardiovascular diseases. The purpose of this study was to determine the contribution of isolated low HDL cholesterol to endothelial function. Thirty-nine subjects with low HDL cholesterol who had no other cardiovascular risk factors were selected from the 5,417 participants from our population. We evaluated flow-mediated vasodilation (FMD) before and after 4 wk of treatment with the HMG-CoA reductase inhibitor pravastatin in 29 of the 39 subjects with isolated low HDL cholesterol. FMD was lower in the low-HDL-cholesterol group (n ϭ 29) than in the control group (n ϭ 29), whereas NTG-induced vasodilation was similar in the two groups. Pravastatin increased HDL cholesterol, urinary excretion of nitrite/nitrate, circulating levels of progenitor cells, and cell migration response to vascular endothelial growth factor in 15 subjects with low HDL cholesterol but not in 14 placebo control subjects. FMD increased in the pravastatin treatment group but not in the control group. NTG-induced vasodilation was similar before and after 4 wk of treatment in the two groups. Multiple regression analysis revealed that changes in HDL cholesterol, the number of progenitor cells, and migration of progenitor cells were independent predictors of augmentation of FMD with pravastatin. These findings suggest that low HDL cholesterol is an independent risk factor for endothelial dysfunction and that pravastatin improves endothelial function in individuals with isolated low HDL cholesterol through, at least in part, an increase in circulating progenitor cells.
EPIDEMIOLOGIC STUDIES HAVE SHOWN that a low level of highdensity lipoprotein (HDL) cholesterol is an independent predictor for risk of cardiovascular diseases (CVD) (1, 18, 26) . HDL has antiatherosclerotic effects, including augmentation of ability of reverse cholesterol transport, anti-inflammation, inhibition of low-density lipoprotein (LDL) cholesterol oxidation, endothelial cell apoptosis, platelet aggregation, expression of adhesion molecules, and reendovascularization (3, 8) .
In addition, studies have suggested that an increase in HDL cholesterol level is related to reduction in the risk of morbidity and mortality of CVD (3a, 17) .
Endothelial dysfunction is the initial step in the development of atherosclerosis, leading to CVD (25) . Several lines of evidence have shown that hypercholesterolemia, one of the risk factors of CVD, is associated with endothelial dysfunction (7, 20, 31) . Studies have shown that cholesterollowering therapy improves endothelium-dependent vasodilation in patients with dyslipidemia (10, 23, 30) . Subjects in those studies included subjects with isolated hypercholesterolemia and/or both hypercholesterolemia and low HDL cholesterol. There is little information regarding the effects of low HDL cholesterol per se under conditions without confounding factors, including hypercholesterolemia, diabetes mellitus, smoking, obesity, and menstrual cycle, that affect endothelial function on endothelium-dependent vasodilation and regarding the effects of an 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) reductase inhibitor on endothelium-dependent vasodilation in subjects with low HDL cholesterol.
The purpose of this study was to evaluate the prevalence of isolated low HDL cholesterol and to assess endothelial function in subjects with low HDL cholesterol who have no other cardiovascular risk factors. We also evaluated the effects of the HMG-CoA reductase inhibitor pravastatin on endothelial function in these subjects.
MATERIALS AND METHODS

Subjects.
A total of 5,417 subjects (3,703 men and 1,714 women; mean age 49 Ϯ 15 yr, age range 22-88 yr) were recruited from people who underwent health screening examinations at Kurume University Hospital and Hiroshima University Hospital. Thirty-nine subjects with low HDL cholesterol who had no other cardiovascular risk factors, such as elevated levels of blood pressure, cholesterol, and glucose and smoking habit (28 men and 11 women; mean age 46 Ϯ 6 yr) were selected from the 5,417 subjects. Tangier disease and hypo-␣-lipoproteinemia were also excluded. After obtaining written, informed consent from subjects to whom the procedure, examination of endothelial function, and effects of lipid-lowering therapy with an HMG-CoA reductase inhibitor had been explained, 29 subjects with low HDL cholesterol (22 men and 7 women; mean age 45 Ϯ 6 yr) out of 39 subjects with low HDL cholesterol and 29 normal healthy subjects as a control group (22 men and 7 women; mean age, 46 Ϯ 7 yr) out of 2,980 healthy subjects among the 5,417 subjects were enrolled in this study. The 29 subjects with low HDL cholesterol were randomly divided into a pravastatin treatment group (n ϭ 15, 11 men and 4 women; mean age 46 Ϯ 8 yr) and a placebo group (n ϭ 14, 11 men and 3 women; mean age 45 Ϯ 9 yr). A flow chart of the study design from screening to completion of the trial is shown in Fig. 1 . Hypertension was defined as systolic blood pressure Ն140 mmHg and/or diastolic blood pressure Ն90 mmHg according to Chobanian et al. (4) and/or the use of antihypertensive medication. Diabetes was defined according to the American Diabetes Association (2) and/or a previous diagnosis of diabetes. Hypercholesterolemia was defined according to the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (11) and/or treatment with lipid-lowering medications. Low HDL cholesterol was defined as Ͻ40 mg/dl (0.9 mmol/l). The ethics committee of our institutes approved the study protocol. Written, informed consent for participation in the study was obtained from all subjects.
Protocol 1: endothelial function in healthy control subjects and subjects with low HDL cholesterol. We measured the vascular responses to reactive hyperemia and sublingual nitroglycerine (NTG) in the brachial artery in 29 subjects with isolated low HDL cholesterol and 29 healthy control subjects. Subjects fasted the previous night for Ն12 h. The study began at 8:30 AM. The subjects were kept in the supine position in a quiet, dark, air-conditioned room (constant temperature 22-25°C) throughout the study. A 23-gauge polyethylene catheter was inserted into the left deep antecubital vein to obtain blood samples. Thirty minutes after the supine position was maintained, basal brachial artery diameter was measured. Then flow-mediated vasodilation (FMD) and NTG-induced vasodilation were measured. These studies were carried out in a randomized fashion. Each study proceeded after brachial artery diameter had returned to baseline.
Baseline fasting serum concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, malondialdehyde (MDA)-modified LDL, glucose, insulin, electrolytes, interleukin-6, and highsensitivity C-reactive protein (hs-CRP) and plasma concentrations of vascular endothelial growth factor (VEGF) were obtained after a 30-min rest period before the study. The 24-h urinary excretion of 8-hydroxy-2Ј-deoxyguanosine (8-OHdG) and that of nitrite/nitrate were determined.
Protocol 2: effect of pravastatin on endothelial function in subjects with low HDL cholesterol. The 29 subjects with isolated low HDL cholesterol who were enrolled in protocol 1 were randomly divided into a pravastatin treatment group (n ϭ 15) and placebo control group (n ϭ 14). Subjects were treated with single daily doses of 10 mg of pravastatin (Dai-ichi Sankyo Pharmaceutical, Tokyo, Japan) in the morning during the 4-wk active treatment period. FMD and NTGinduced vasodilation were evaluated in a manner identical to that of protocol 1 in all subjects at 0 and 4 wk of followup.
Baseline fasting serum concentrations of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, MDA-modified LDL, glucose, insulin, electrolytes, interleukin-6, and hs-CRP and plasma concentrations of VEGF were obtained after a 30-min rest period before the study at 0 and 4 wk of followup. The 24-h urinary excretion of 8-OHdG and that of nitrite/nitrate were determined at 0 and 4 wk of followup.
Measurement of vascular function. Vascular responses to reactive hyperemia and NTG in the brachial artery were assessed in accordance with the guidelines for ultrasound assessment of endotheliumdependent FMD (6) . Briefly, the subjects underwent a study of vascular function using ultrasound equipment and a high-resolution linear artery transducer (13 MHz) coupled to computer-assisted analysis software (e-TRACKING system; Aloka, Tokyo, Japan) that used an automated edge detection system for measurement of brachial artery diameter (28) . To ensure consistency of the image, the right arm of the subject was fixed by a special arm-holding device (MIST-100; Saraya, Osaka, Japan), and the transducer was held at the same point throughout the scan by a special probe holder (MP-PH0001; Aloka). The response to NTG was used for assessment of endotheliumindependent vasodilation. After baseline rest image was acquired for 30 s, a sublingual tablet (75 g NTG; Nihonkayaku, Tokyo, Japan) was given, and image of the artery was recorded continuously for 5 min. The response of brachial artery diameter to NTG was expressed immediately as percent change relative to vessel diameter. NTGinduced vasodilation was automatically calculated as a percent change in peak vessel diameter from the baseline value. %NTG (peak diameter-baseline diameter/baseline diameter) was used for analysis.
Measurement of number of circulating progenitor cells. The number of circulating progenitor cells was analyzed by flow cytometry. Briefly, samples of venous blood were placed in tubes containing sodium EDTA (7 mg/ml) and in polystyrene tubes. The EDTAcontaining tubes were chilled promptly in an ice bath. Peripheral blood mononuclear cells were immediately isolated by Ficoll density gradient centrifugation (Axis-Shield; Dundee). After thawing, 10 6 peripheral blood mononuclear cells were incubated for 10 min with monoclonal antibodies against human FITC-conjugated anti-CD45 (Miltenyi Biotec, Bergisch Gladbach, Germany), PE-conjugated anti-AC133 (Miltenyi Biotec), and APC-conjugated anti-CD34 monoclonal antibody (Becton-Dickinson Biosciences, Franklin Lakes, NJ). To assess background, isotype controls were used as negative controls based on the species and IgG subclass of each antibody. After incubation, erythrocytes were lysed, and the remaining cells were washed with phosphate-buffered saline, fixed in 2% paraformaldehyde, and analyzed on a FACS Calibur Flow Cytometer (BectonDickinson Biosciences). Each analysis consisted of 500,000 events. To quantify the amount of CD34 ϩ AC133 ϩ CD45 low cells, the mononuclear cell fraction was gated and analyzed for the expression of AC133 and CD45. Only AC133 ϩ CD45 low cells were finally investigated for the count of CD34 ϩ cells. Characterization of progenitor cells. Mononuclear cells were isolated by Ficoll density gradient centrifugation of human blood buffy coats from 50 ml of peripheral blood. Then, 1 ϫ 10 4 mononuclear cells were plated on six-well culture dishes coated with human fibronectin and gelatin and maintained in endothelial cell basal medium (EBM)-2 (CellSystem) supplemented with endothelial growth medium-2 microvascular single aliquots and 5% fetal bovine serum. After 3 days of culture, nonadherent cells were removed. Cytochemical analysis of adherent cells was performed on day 4. To detect the uptake of 1,1Ј-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine-labeled acetylated LDL (Dil-AcLDL; Molecular Probes, Carlsbad, CA), cultivated cells were incubated with Dil-AcLDL (10 g/ml) at 37°C for 1 h. Thereafter, cells were fixed with 2% paraformaldehyde for 10 min and incubated with FITC-labeled Ulex europaeus agglutinin I (lectin, 10 g/ml; Sigma) for 1 h. Cells demonstrating double-positive staining lectin and Dil-AcLDL were identified to be progenitor cells. Three randomly selected high-power fields per well were counted.
Migration assay. Progenitor cell migration was evaluated using a modified Boyden chamber assay, as described previously (9) . Briefly, isolated progenitor cells were detached mechanically by using a cell scraper, harvested by means of centrifugation and resuspended in 300 l of EBM, and counted. The 2 ϫ 10 4 progenitor cells were placed in 
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the upper chamber of a modified Boyden chamber (FluroBlock; Becton-Dickinson Biosciences). The chamber was placed in a 24-well culture dish containing EBM and culture medium for control and human recombinant VEGF (50 ng/ml; Sigma). After 24 h of incubation at 37°C, the lower side of the filter was washed with PBS and fixed with 2% paraformaldehyde. For quantification of cells that had migrated, cell nuclei were stained with 4Ј,6-diamino-2-phenylidole (Sigma). Migrated cells in the lower chamber were counted manually in the three random high-power fields. Each experiment was performed in triplicate. Analytical methods. Samples of venous blood were placed in tubes containing sodium EDTA (1 mg/ml) and in polystyrene tubes. The EDTA-containing tubes were chilled promptly in an ice bath. Plasma was immediately separated by centrifugation at 3,100 g for 10 min at 4°C, and serum was separated by centrifugation at 1,000 g for 10 min at room temperature. Samples were stored at Ϫ80°C until the time of assay. Serum concentrations of total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, glucose, and electrolytes were determined by routine chemical methods. Plasma concentrations of VEGF were measured using ELISA kits (R & D Systems, Minneapolis, MN). Serum concentration of hs-CRP was measured by a highly sensitive nephelometry assay using a CRP kit (Dade Behring, Deerfield, IL). Serum concentration of interleukin-6 was measured by a high-sensitivity ELISA (R & D Systems). The serum concentration of MDA-LDL was assayed by ELISA (anti-MDA-modified LDL antibody; SRL, Atsugi, Japan). The urinary excretion of 8-OHdG also was assayed by ELISA using 8-OHdG kits (Nihon Yushi, Fukuroi, Japan).
Statistical methods. Values are expressed as means Ϯ SD. All reported P values were two-tailed. Results were considered significant at P Ͻ 0.05. The Mann-Whitney U-test was used to evaluate differences before and after administration of pravastatin with respect to baseline parameters. Two-tailed Student's paired t-test was used to evaluate differences before and after administration of pravastatin. FMD and NTG-induced vasodilation before and after administration of pravastatin were analyzed by two-way ANOVA for repeated measurements, followed by Scheffé's F-test. Comparisons of time course curves of parameters during administration of pravastatin or placebo were analyzed by two-way ANOVA for repeated measurements on one factor followed by Bonferroni correction for multiple paired comparisons. Relationships between variables were determined by linear regression analysis. Multivariate linear regression analysis was performed to explain variability of changes in FMD. The data were processed using the software package StatView IV (SAS Institute, Cary, NC) or Super analysis of variance (Abacus Concepts, Berkeley, CA).
RESULTS
Protocol 1.
Thirty-nine (0.72%) of the 5,417 subjects had isolated low HDL cholesterol with no other cardiovascular risk factors, such as elevated levels of blood pressure, cholesterol, and glucose and smoking habit. The baseline clinical characteristics of the healthy subjects group and isolated low HDL cholesterol group are shown in Table 1 . Serum concentrations of HDL and urinary nitrite/nitrate excretion were significantly lower in subjects with isolated HDL cholesterol than in healthy control subjects.
FMD was significantly less in subjects with low HDL cholesterol than in healthy control subjects (7.9 Ϯ 2.5 vs. 11.1 Ϯ 2.7%, P ϭ 0.02; Fig. 2, top left) . Vasodilatory responses to sublingual NTG were similar in the two groups (Fig.  2, top right) .
The numbers of circulating progenitor cells and cell migration response to VEGF were similar in the control group and isolated low-HDL group (908 Ϯ 267 vs. 824 Ϯ 272 cells/ml and 34.0 Ϯ 17.9 vs. 31.7 Ϯ 19.8 cells/highpower field; Fig. 3B, left) . There was no significant difference in other parameters between the two groups.
Protocol 2. The baseline clinical characteristics of the pravastatin treatment group and placebo group are shown in Table  1 . There was no significant difference in baseline clinical characteristics between the placebo and pravastatin treatment groups at 0 wk of followup. The 4 wk of pravastatin treatment Table 1 
. Clinical characteristics of healthy control subjects and subjects with low HDL-C and subjects with low HDL-C before and after pravastatin therapy
Variables Control (n ϭ 29) Low HDL-C (n ϭ 29)
Low HDL-C Placebo (n ϭ 14) Pravastatin (n ϭ 15) significantly increased serum concentrations of HDL cholesterol (P Ͻ 0.001) and urinary nitrite/nitrate excretion (P ϭ 0.04) and decreased, but not significantly, serum concentrations of total cholesterol (P ϭ 0.06). Pravastatin treatment did not alter other parameters. In the placebo group, the baseline clinical characteristics were similar at 0 and 4 wk of followup.
FMD was increased significantly from 7.2 Ϯ 2.4 to 9.8 Ϯ 2.8% (P ϭ 0.02) by 4 wk of treatment, whereas there was no significant difference between FMD in the placebo group before and after the 4-wk study period. FMD was greater in the pravastain group than in the control group (P ϭ 0.03; Fig. 2,  bottom left) . NTG-induced vasodilations were similar at the beginning and the end of the 4-wk study period in both groups. NTG-induced vasodilations were similar in the two groups (Fig. 2, bottom right) .
Pravastatin treatment for 4 wk increased the number of circulating progenitor cells from 794 Ϯ 293 to 10,741 Ϯ 304 cells/ml (P ϭ 0.01) and cell migration response to VEGF from 32.1 Ϯ 21.8 to 43.1 Ϯ 18.2 cells/high-power field (P ϭ 0.03), whereas there were no significant differences between the number of circulating progenitor cells and cell migration response to VEGF at 0 wk and that at 4 wk in the placebo group. The number of circulating progenitor cells was greater in the pravastain group than in the control group (P ϭ 0.04). There was no significant difference in migration of progenitor cells between the two groups (P ϭ 0.09; Fig. 3B, right) .
Changes in FMD correlated with changes in HDL cholesterol levels (r ϭ 0.43, P ϭ 0.01; Fig. 4, top) , changes in number of circulating progenitor cells (r ϭ 0.68, P Ͻ 0.001; Fig. 4, middle) , and changes in cell migration response to VEGF (r ϭ 0.38, P ϭ 0.04; Fig. 4, bottom) in the pravastatin group but not in the placebo group. Changes in FMD did not correlate with changes in other parameters in the two groups. There was a significant relationship between changes in HDL cholesterol levels and changes in the number of progenitor cells (r ϭ 0.41, P ϭ 0.02) in the pravastatin group but not in the placebo group. Changes in HDL cholesterol levels did not correlate with changes in cell migration response to VEGF. There was a significant relationship between changes in the number of progenitor cells and changes in cell migration response to VEGF (r ϭ 0.49, P ϭ 0.005) in the pravastatin group but not in the placebo group. Changes in NTG-induced vasodilation did not correlate with changes in any parameters in the pravastatin group and the placebo group. By multivariate linear regression analysis, changes in HDL cholesterol, number of progenitor cells, and migration of progenitor cells were identified as independent predictors for changes in FMD with pravastatin treatment (Table 2) . Fig. 2 . Comparison of flow-mediated vasodilation (FMD) and nitroglycerine (NTG)-induced vasodilation in normal healthy subjects and subjects with isolated low HDL cholesterol (top) at 0 and 4 wk of followup in the placebo group and pravastatin treatment group (bottom). *P ϭ 0.02 vs. 0 wk in the pravastatin treatment group. NS, not significant.
DISCUSSION
To confirm the effects of low HDL per se on endothelial function, subjects with isolated low HDL and without cardiovascular risk factors, which influence endothelial function, were recruited. Thirty-nine (0.72%) of the 5,417 subjects were enrolled in the present study. FMD and urinary excretion of nitrite/nitrate were smaller in subjects with isolated low HDL cholesterol than in controls. Four-week treatment with the HMG-CoA reductase inhibitor pravastatin increased HDL cholesterol, circulating number of progenitor cells, migration of endothelial progenitor cells, urinary excretion of nitrite/nitrate, and FMD in subjects with isolated low HDL cholesterol. Multiple regression analysis revealed that changes in HDL cholesterol, number of progenitor cells, and migration of progenitor cells were predictors of augmentation of FMD with pravastatin treatment.
Subjects with isolated low HDL cholesterol have no classical cardiovascular risk factors, which influence endothelial function. In addition, other confounding factors, such as oxidative stress markers, inflammation markers, circulating num- Fig. 3 . A: measurement of the number of progenitor cells by flow cytometry at 0 and 4 wk of pravastatin treatment (top). B: comparison of the number of progenitor cells in normal healthy subjects and that in subjects with isolated low HDL cholesterol and at 0 and 4 wk of followup in the placebo group and pravastatin treatment group. *P ϭ 0.01 vs. 0 wk in the pravastatin treatment group. C: characterization of progenitor cells by immunofluoresence for lectin binding (green), 1,1Ј-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine-labeled acetylated LDL (Dil-AcLDL) uptake (red), and lectin/Dil-AcLDL double-positive cells (yellow) (ϫ200). D: measurement of the migration of cells labeled with 4Ј,6-diamino-2-phenylidole by fluoresence at 0 and 4 wk of pravastatin treatment (ϫ200). E: comparison of the migration of progenitor cells in normal healthy subjects and subjects with isolated low HDL cholesterol at 0 and 4 wk of followup in the placebo group and pravastatin treatment group. *P ϭ 0.03 vs. 0 wk in the pravastatin treatment group. SSC, side scatter; FSC, forward scatter.
bers of progenitor cells, and cell migration response to VEGF, were similar in subjects with isolated low HDL cholesterol and controls. FMD and urinary excretion of nitrite/nitrate decreased in subjects with isolated low HDL cholesterol. These findings suggest that low HDL cholesterol per se impaired endothelial function through a decrease in nitric oxide (NO).
Several lines of evidence indicate that HDL per se has beneficial antiatherosclerotic effects (3, 8) . HDL acts as a reverse cholesterol transporter by removing excess cellular cholesterol to the liver, resulting in protection against atherosclerosis. Although the reverse cholesterol transport pathway is a predominant antiatherosclerotic effect of HDL, HDL has multifactorial effects to protect vascular function. HDL activates endothelial NO synthase by enhancing Akt and MAP kinases, leading to an increase in NO, suppresses endothelial cell apoptosis by activation of the Akt pathway and inhibition of caspase-3 and -9, inhibits the oxidation of LDLs, limits inflammation processes, stimulates prostcyclin production, and upregulates cyclooxygenase-2 expression, leading to anticoagulation and vasodilation (3, 5, 8, 19) . Therefore, under a low HDL cholesterol condition, atherosclerotic processes develop progressively, resulting in cardiovascular outcomes.
Several mechanisms by which pravastatin improves endothelial function have been postulated. It is well known that statins augment endothelium-dependent vasodilation through an increase in NO bioavailability (e.g., activation of phosphatidylinositol 3-kinase/Akt pathway, increase in endothelial NO synthase mRNA stability, and decrease in oxidative stress and inflammation) (16, 24) . In the present study, an increase in the number of progenitor cells and cell migration response to VEGF were associated with an increase in FMD after pravastatin therapy. Recently, Hill et al. (15) . also found by measurements of FMD in healthy men that the number of circulating progenitor cells is correlated with endothelial function. One possible mechanism by which pravastatin improves endothelial function is increasing the circulating number of progenitor cells, which may lead to an increase in NO and reendovascularization. Pravastatin-induced increase in HDL choles- (22, 27) . Augmentation or improvement in endothelial function by a statin may contribute to reduction in cardiovascular outcomes in patients with CVD as well as dyslipidemia.
A balance between ambient levels of superoxide and NO release plays a critical role in the maintenance of normal endothelial function (13, 14, 21) . Hypercholesterolemia is associated with oxidative stress and endothelial dysfunction (12) . In the present study, there were no significant differences in urinary 8-OHdG excretion and serum MDA-LDL concentration between isolated low-HDL cholesterol subjects and controls, suggesting that oxidative stress is not enhanced in isolated low-HDL cholesterol subjects. In addition, pravastatin did not alter oxidative stress markers in these subjects. It is unlikely that pravastatin-induced augmentation of endothelial function is due to a decrease in oxidative stress in isolated low-HDL cholesterol subjects.
It is well known that there is an association between inflammation and endothelial dysfunction. Low HDL per se may cause inflammation. However, in the present study, isolated low-HDL cholesterol subjects had no increased inflammation markers such as interleukin-6 and hs-CPR. In addition, pravastatin did not alter inflammation markers in these subjects.
The present study lacks a regimen for pravastatin treatment in the control subjects to determine whether the effect of pravastatin on FMD is specific for subjects with low HDL cholesterol or general for healthy subjects. Measurements of FMD before and after administration of pravastatin in control subjects who have normal levels of HDL cholesterol may enable a more specific conclusion concerning the role of HDL in endothelial function to be made.
In the present study, concentrations of LDL cholesterol and triglycerides tended to be decreased, but not significantly, after pravastatin treatment. We cannot deny the possibility that changes in lipids other than HDL may have contributed to the improvement in FMD following pravastatin.
In conclusion, isolated low HDL cholesterol per se is an independent risk factor for endothelial dysfunction in humans. The HMG-CoA reductase inhibitor pravastatin improves endothelial function in individuals with isolated low HDL cholesterol through, at least in part, increasing HDL cholesterol levels and increasing the number of progenitor cells and enhancing the function of progenitor cells.
